Name : Aquib Nawaz(33Y/M)
Date : 17 May 2025
Test Asked : Crm
Report Status: Complete Report
PROCESSED AT :
Thyrocare
106, Shreegopal,
Jessore Rd, Madhyamgram
Kolkata-700129
NAME : AQUIB NAWAZ(33Y/M) HOME COLLECTION :
REF. BY : SELF
B-53 RBI OFFICERS QUARTER ULTADANGA
TEST ASKED : CRM INFRONT OF BIDHAAN NAGAR STATION
Report Availability Summary
Note: Please refer to the table below for status of your tests.
3 Ready 0 Ready with Cancellation 0 Processing 0 Cancelled in Lab
TEST DETAILS REPORT STATUS
CRM Ready
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) Ready
Lipoprotein (a) [Lp(a)] Ready
APOLIPROTEIN RATIO Ready
PROCESSED AT :
Thyrocare
106, Shreegopal,
Jessore Rd, Madhyamgram
Kolkata-700129
NAME : AQUIB NAWAZ(33Y/M) HOME COLLECTION :
REF. BY B-53 RBI OFFICERS QUARTER ULTADANGA
: SELF
INFRONT OF BIDHAAN NAGAR STATION
TEST ASKED : CRM
TEST NAME TECHNOLOGY VALUE UNITS
APOLIPOPROTEIN - A1 (APO-A1) IMMUNOTURBIDIMETR 120 mg/dL
Y
Bio. Ref. Interval. :
Male : 86 - 152
Female : 94 - 162
Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER
APOLIPOPROTEIN - B (APO-B) IMMUNOTURBIDIMETR 106 mg/dL
Y
Bio. Ref. Interval. :
Male : 56 - 145
Female : 53 - 138
Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER
APO B / APO A1 RATIO (APO B/A1) CALCULATED 0.9 Ratio
Bio. Ref. Interval. :
Male : 0.40 - 1.26
Female : 0.38 - 1.14
Clinical Significance :
• Apolipoprotein B is a more potent and independent predictor of Coronary artery disease (CAD) than LDL Cholesterol.
• Apolipoprotein A1 is one of the apoproteins of HDL and is inversely related to risk of CAD.
• The Apolipoprotein studies help in monitoring risk of restenosis in patients with myocardial infarction, Coronary bypass surgery etc.
• An increased ratio of Apo B to A1 beyond the defined normal range is indicative of CAD risk.
• All results have to be interpreted in Conjunction with clinical history and other findings.
Method : Derived from serum Apo A1 and Apo B values
Please correlate with clinical conditions.
Sample Collected on (SCT) : 17 May 2025 10:27
Sample Received on (SRT) : 17 May 2025 14:02
Report Released on (RRT) : 17 May 2025 15:13
Sample Type : SERUM
Labcode : 1705080537/PP004 Dr Shibasis MD (Biochemist)
Barcode : DO977488
Page : 1 of 4
Scan QR code to verify authenticity of reported results; active for 30 days from release time.
PROCESSED AT :
Thyrocare
106, Shreegopal,
Jessore Rd, Madhyamgram
Kolkata-700129
NAME : AQUIB NAWAZ(33Y/M) HOME COLLECTION :
REF. BY : SELF B-53 RBI OFFICERS QUARTER ULTADANGA
INFRONT OF BIDHAAN NAGAR STATION
TEST ASKED : CRM
TEST NAME TECHNOLOGY VALUE UNITS
Lipoprotein (a) [Lp(a)] IMMUNOTURBIDIMETRY 9.43 mg/dL
Bio. Ref. Interval. :-
Adults : < 30.0 mg/dl
Clinical Significance:
Determination of LPA may be useful to guide management of individuals with a family history of CHD or with existing disease. The
levels of LPA in the blood depends on genetic factors; The range of variation in a population is relatively large and hence for
diagnostic purpose, results should always be assessed in conjunction with the patient’s medical history, clinical examination and
other findings.
Specifications:
Precision %CV :- Intra assay %CV- 4.55% , Inter assay %CV-0.86 %
Kit Validation Reference:
Tietz NW,Clinical Guide to Laboratory Tests Philadelphia WB. Saunders 1995 : 442-444
Please correlate with clinical conditions.
Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY
Sample Collected on (SCT) : 17 May 2025 10:27
Sample Received on (SRT) : 17 May 2025 14:02
Report Released on (RRT) : 17 May 2025 15:13
Sample Type : SERUM
Dr Shibasis MD (Biochemist)
Labcode : 1705080537/PP004
Barcode : DO977488 Page : 2 of 4
PROCESSED AT :
Thyrocare
106, Shreegopal,
Jessore Rd, Madhyamgram
Kolkata-700129
NAME : AQUIB NAWAZ(33Y/M) HOME COLLECTION :
REF. BY : SELF B-53 RBI OFFICERS QUARTER ULTADANGA
INFRONT OF BIDHAAN NAGAR STATION
TEST ASKED : CRM
TEST NAME TECHNOLOGY VALUE UNITS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IMMUNOTURBIDIMETRY 2.83 mg/L
Bio. Ref. Interval. :-
< 1.00 - Low Risk
1.00 - 3.00 - Average Risk
>3.00 - 10.00 - High Risk
> 10.00 - Possibly due to Non-Cardiac Inflammation
Disclaimer: Persistent unexplained elevation of HSCRP >10 should be evaluated for non-cardiovascular etiologies such as
infection , active arthritis or concurrent illness.
Clinical significance:
High sensitivity C- reactive Protein ( HSCRP) can be used as an independent risk marker for the identification of Individuals at risk
for future cardiovascular Disease. A coronary artery disease risk assessment should be based on the average of two hs-CRP
tests, ideally taken two weeks apart.
Kit Validation Reference:
1.Clinical management of laboratory date in medical practice 2003-3004, 207(2003).
2.Tietz : Textbook of Clinical Chemistry and Molecular diagnostics :Second edition :Chapter 47:Page no.1507- 1508.
Please correlate with clinical conditions.
Method:- FULLY AUTOMATED LATEX AGGLUTINATION – BECKMAN COULTER
~~ End of report ~~
Sample Collected on (SCT) : 17 May 2025 10:27
Sample Received on (SRT) : 17 May 2025 14:02
Report Released on (RRT) : 17 May 2025 15:13
Sample Type : SERUM
Dr Shibasis MD (Biochemist)
Labcode : 1705080537/PP004
Barcode : DO977488 Page : 3 of 4
Scan QR code to verify authenticity of reported results; active for 30 days from release time.
CONDITIONS OF REPORTING
v The reported results are for information and interpretation of the referring doctor only.
v It is presumed that the tests performed on the specimen belong to the patient; named or identified.
v Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same
patient.
v Should the results indicate an unexpected abnormality, the same should be reconfirmed.
v Only such medical professionals who understand reporting units, reference ranges and limitations of technologies
should interpret results.
v This report is not valid for medico-legal purpose.
v Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage
that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims
of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for
indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the
total amount of invoice for the services provided and paid for.
v Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
EXPLANATIONS
v Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them
as "Clients".
v Name - The name is as declared by the client and recored by the personnel who collected the specimen.
v Ref.Dr - The name of the doctor who has recommended testing as declared by the client.
v Labcode - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
v Barcode - This is the specimen identity number and it states that the results are for the specimen bearing
the barcode (irrespective of the name).
v SCP - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by
the client.
v SCT - Specimen Collection Time - The time when specimen was collected as declared by the client.
v SRT - Specimen Receiving Time - This time when the specimen reached our laboratory.
v RRT - Report Releasing Time - The time when our pathologist has released the values for Reporting.
v Reference Range - Means the range of values in which 95% of the normal population would fall.
SUGGESTIONS
v Values out of reference range requires reconfirmation before starting any medical treatment.
v Retesting is needed if you suspect any quality shortcomings.
v Testing or retesting should be done in accredited laboratories.
v For suggestions, complaints, clinical support or feedback, write to us at [email protected]
or call us on 022-3090 0000
+ T&C Apply, #As on 5th December 2024, *As per a survey on doctors' perception of laboratory diagnostics (IJARIIT,2023)
Page : 4 of 4
